Table III.
Study (year) | Treatment | Patients | End points (months) | HR (95% CI) | p value |
---|---|---|---|---|---|
Giantonio et al E3200 (2007) | Bevacizumab vs. FOLFOX4 vs. FOLFOX4+ Bevacizumab | 829 (820) | OS (10.2 vs. 10.8 vs. 12.9) | 0.76 (NS) | 0.0018 |
243vs.291vs.286 | PFS (2.7 vs. 4.7 vs. 7.3) | 0.75 (NS) | 0.0011 | ||
Grothey et al CORRECT (2013) | placebo vs. Regorafenib | 760 | OS (5.0 vs. 6.4) | 0.77 (0.64–0.94) | 0.0052 |
255 vs. 505 | PFS (1.7 vs. 1.9) | 0.49 (0.42-0.58) | <0.0001 |